- Home
- SBAC vs MRNA Comparison
SBAC vs MRNA Comparison
Compare SBAC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBAC | MRNA |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8B | 21.6B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SBAC | MRNA |
|---|---|---|
| Price | $181.76 | $59.64 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 12 |
| Target Price | ★ $233.12 | $34.27 |
| AVG Volume (30 Days) | 920.5K | ★ 6.9M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ 41.21 | 21.77 |
| EPS | ★ 1.74 | N/A |
| Revenue | $2,815,139,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $2.80 | $9.36 |
| Revenue Next Year | $2.76 | $15.43 |
| P/E Ratio | $103.85 | ★ N/A |
| Revenue Growth | ★ 5.06 | 4.29 |
| 52 Week Low | $162.41 | $22.28 |
| 52 Week High | $243.16 | $67.74 |
Technical Indicators
Market Signals| Indicator | SBAC | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 31.49 | 61.56 |
| Support Level | $178.69 | $45.69 |
| Resistance Level | $193.78 | N/A |
| Average True Range (ATR) | 6.03 | 4.46 |
| MACD | -1.74 | 1.16 |
| Stochastic Oscillator | 9.69 | 63.56 |
Price Performance
Historical ComparisonAbout SBAC SBA Communications Corporation
SBA Communications owns a portfolio of about 46,000 wireless towers throughout North America, South America, and Africa. It leases space on its towers to wireless service providers, who install equipment to support their wireless networks. The company has a very concentrated customer base, with most revenue in each market generated by the top three or four mobile carriers. It owns more than 17,000 towers in the US, which account for about 70% of leasing revenue. Internationally, SBA's largest markets are Brazil and Guatemala, where it owns roughly 12,000 and 5,000 towers, respectively. SBA operates as a real estate investment trust.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.